Driscoll was born in Elmhurst, Illinois, on October 4th, 1933. He spent most of his life in the Chicago area but moved to ...

Bladder cancer is largely a disease of the elderly ... @zklaassen_md on Twitter during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, Fri, May 31 – Tues, June 4, ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...

Bladder cancer is one of the most common malignant tumors in urinary system, and the treatment faces huge challenges.

Researchers discover novel targets for bladder cancer therapeutics and demonstrate that a new combination of existing drugs, including statins, blocks tumor growth in mice.

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.

The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...

(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...

Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational ...